Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria

Archives of Gynecology and Obstetrics

Volumn 293, Issue 2, 2016, Pages 447-456

  Jamil, Avin S ^a   Alalaf, Shahla K ^a   Al Tawil, Namir G ^a   Al Shawaf, Talha ^b  

^a HAWLER MEDICAL UNIVERSITY   (Iraq)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti mullerian hormone; Hyperandrogenism; Obesity; PCOS; Rotterdam PCOS phenotypes

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACANTHOSIS NIGRICANS; ACNE; ADULT; ANOVULATION; ARTICLE; BODY MASS; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HAIR LOSS; HIRSUTISM; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; MORPHOLOGY; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; TESTOSTERONE BLOOD LEVEL; ADOLESCENT; BLOOD; METABOLISM; OVARY; PATHOLOGY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; ANOVULATION; ANTI-MULLERIAN HORMONE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; OVARY; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84954381369     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3889-5     Document Type: Article

References (48)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol and Metab 89:2745–2749
2. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
3. Xu X, Shi Y, Cui Y, Ma J, Che L, Chen ZJ (2012) Endocrine and metabolic characteristics of polycystic ovary syndrome in Chinese women with different phenotypes. Clin Endocrinol (Oxford) 76:425–430
4. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR (eds) polycystic ovary syndrome. Blackwell Scientific, Boston, pp 377–384
5. National Institute of Health (NIH) (2012). Evidence-based methodology workshop on polycystic ovary syndrome, http://preventionnih.gov/doc/programs/pcos/Finalreport.pdf. Accessed 22 Jan 2014
6. Findlay JK, Drummond AE, Dyson ML, Baillie AJ, Robertson DM, Ethier JF (2002) Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol Cell Endocrinol 191:35–43
7. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D (2009) Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 296:E238–E243
8. Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H (2013) Serum anti-mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 170:157–161
9. Welt CK, Gudmundsson JA, Arsson G, Adams J, Palsdottir H, Gudlaugsdottir G et al (2006) Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 91:4842–4848
10. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P (2006) Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metabol 91:3922–3927
11. Pehlivanov B, Orbetzova M (2007) Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecol Endocrinol 23:604–609
12. Yilmaz M, Isaoglu U, Delibas IB, Kadanali S (2011) Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynecol Research 37:1020–1026
13. Katz AS, Goff DC, Feldman SR (2000) Acanthosis nigricans in obese patients: presentations and implication for atherosclerotic vascular disease. Dermatol Online J 6(1):1–24
14. Hatch R, Rosenfield RL, Kim MH, Tredway D (1981) Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140:815–830
15. Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J (2000) Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens and insulin. Fertil Steril 74(1):49–58
16. Balen AH, Dresner M, Scott EM, Drife JO (2006) Should obese women with polycystic ovary syndrome receive treatment for infertility? Br Med J 332:434–435
17. WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163
18. Carter GD, Holland SM, Alaghband-Zadeh J, Rayman G, Dorrington-Ward P, Wise PH (1983) Investigation of hirsutism: testosterone is not enough. Ann Clin Biochem 20:262–263
19. Balen AH, Laven JS, Tan SL, Dewailly D (2003) Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9:505–514
20. Baldani DP, Skrgatić L, Simunić V, Zlopasa G, Canić T, Trgovcić I (2013) Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population. Collegium Antropologicum 37(2):477–482
21. Kar S (2013) Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: a prospective study of PCOS women. J Hum Reprod Sci 6:194–200
22. Kavardzhikova S, Pechlivanov B (2010) Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, Bulgarian population. Akush Ginekol (Sofiia) 49(4):32–37
23. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A (2007) Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 88(5):1389–1395
24. Mehrabian F, Khani B, Kelishadi R, Kermani N (2011) The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 16(6):763–769
25. Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J (2013) Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study. Arch Gynecol Obstet 287:525–531
26. Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD (2008) Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 198:670
27. Barber TM, Wass JA, McCarthy MI, Frank S (2007) Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol 66:513–517
28. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA (2005) Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90:2545–2549
29. Huber-Buckholz MM, Carey DG, Norman RJ (1999) Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84:1470–1474
30. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA (2003) Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 11:2289–2293
31. Di Fede G, Mansueto P, Longo RA, Rini G (2009) Carmina E (2009) Influence of socio-cultural factors on the ovulatory status of polycystic ovary syndrome. Fertil Steril 91:1853–1856
32. Pasquali R, Gambineri A, Pagotto U (2006) The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113:1148–1159
33. Guastella E, Longo RA, Carmina E (2010) Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 94:2197–2201
34. Hickey TE, Marrocco DL, Amato F, Ritter LJ, Norman RJ, Gilchrist RB et al (2005) Androgens augment the mitogenic effects of oocyte-secreted factors and growth differentiation factor 9 on porcine granulosa cells. Biol Reprod 73:825–832
35. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC (2004) Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89:318–323
36. Cook CL, Siow Y, Brenner AG, Fallat ME (2002) Relationship between serum Müllerian inhibiting substance and other reproductive hormones in untreated women in PCOS and normal women. Fertil Steril 77:141–146
37. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S et al (2003) Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88:5957–5962
38. Broekmans FJ, Visser JA, Laven JS, Broer SL, Themmen AP, Fauser BC (2008) Anti-Mullerian hormone and ovarian dysfunction. Trends Endocrinol Metab 19:340–347
39. Caglar GS, Kahyaoglu I, Pabuccu R, Demirtas S, Seker R (2013) Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet 288:905–910
40. De Vet A, Laven JS, de Jong F, Themmen A, Fauser BC (2002) Anti- Müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77:357–362
41. Duijkers IJ, Klipping C (2010) Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol 26:152–160
42. Casser S, Teede HJ, Moran LJ, Joham AE, Harrison CL, Strauss BJ et al (2014) Polycystic ovary syndrome and anti-Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol 81:899–906
43. Ramanand SJ, Ghongane BB, Ramanand JB, Patwardhan MH, Ghanghas RR, Jain SS (2013) Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocrinol Metab 17:138–145
44. Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q (2014) Anthropometric and biochemical characteristics of polycystic ovarian syndrome in south indian women using AES-2006 criteria. Int J Endocrinol Metab 12(1):e12470
45. Farhan YM, Taher MA, Alhadithy EM (2012) Comparative study on cardiovascular risk factors in newly diagnosed patients with polycystic ovary syndrome (PCOS) and PCOS patients who are on drug metformin. Internat J Sci Nat 3(1):24–29
46. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456–488
47. Woo HY, Kim KH, Rhee EJ, Park H, Lee MK (2012) Differences of the association of anti- Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr 59:781–790
48. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T (2015) A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health 12:7